Piramal Pharma vs Sai Life Sciences vs Neuland Laboratories: Which Stock Should You Track

Piramal Pharma PE NA, mkt cap Rs 28,045 crore. Sai Life Sciences PE 94.54, mkt cap Rs 34,201 crore. Neuland Laboratories PE 57.98, mkt cap Rs 28,859 crore.

Updated: 24 Sept 2026 • 9:56 am

Posted by:

Piramal Pharma vs Sai Life Sciences vs Neuland Laboratories: Which Stock Should You Track

Quick Answer

Piramal Pharma vs Sai Life Sciences vs Neuland Laboratories is a side-by-side comparison of three companies from the CRAMS and Pharma CDMO space. On this comparison, Piramal Pharma carries a market capitalisation of about Rs 28,045 crore against Rs 34,201 crore for Sai Life Sciences and Rs 28,859 crore for Neuland Laboratories, with return on equity of -3.58%, 14.05% and 19.42% respectively. Each company's numbers are presented here without a declared better pick, since the right stock depends on an investor's own criteria.

Piramal Pharma vs Sai Life Sciences vs Neuland Laboratories starts with the core numbers most investors compare within the CRAMS and Pharma CDMO segment: market capitalisation, valuation multiples, profitability and dividend yield. Figures below are sourced as of September 2026 and will shift with daily price moves.

All three names sit in the CRAMS and Pharma CDMO bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses.

Click Here – Get Free Investment Predictions

Table of Contents

Piramal Pharma, Sai Life Sciences and Neuland Laboratories: Company Overview

Piramal Pharma is a listed Indian company in the CRAMS and Pharma CDMO space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.

Sai Life Sciences is a listed Indian company in the CRAMS and Pharma CDMO space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.

Neuland Laboratories is a listed Indian company in the CRAMS and Pharma CDMO space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.

Piramal Pharma vs Sai Life Sciences vs Neuland Laboratories: Valuation and Profitability Snapshot

Metric	Piramal Pharma	Sai Life Sciences	Neuland Laboratories
Market Cap (approx.)	Rs 28,045 crore	Rs 34,201 crore	Rs 28,859 crore
PE Ratio (TTM)	NA	94.54	57.98
PB Ratio	3.43	13.77	15.40
Return on Equity (ROE)	-3.58%	14.05%	19.42%
EPS (TTM, Rs)	-2.36	17.03	387.98
Dividend Yield	0.00%	0.00%	0.15%
Debt to Equity	0.70	0.12	0.16
Book Value per Share (Rs)	61.34	116.93	1460.31

Check the Univest Screener for Live Data

On valuation, Piramal Pharma trades at a PE of NA and a PB of 3.43, Sai Life Sciences at a PE of 94.54 and a PB of 13.77, while Neuland Laboratories trades at a PE of 57.98 and a PB of 15.40. On return on equity, the three post -3.58%, 14.05% and 19.42% respectively, and on dividend yield they stand at 0.00%, 0.00% and 0.15%.

Piramal Pharma vs Sai Life Sciences vs Neuland Laboratories: Latest Quarterly Results

Company	Latest Quarter Revenue	Latest Quarter Net Profit	YoY Change (Revenue)	QoQ Change (Revenue)
Piramal Pharma	Rs 2,359.33 crore	Rs -69.39 crore	+18.4%	-15.7%
Sai Life Sciences	Rs 557.83 crore	Rs 73.29 crore	+10.2%	-9.7%
Neuland Laboratories	Rs 650.07 crore	Rs 147.67 crore	+116.3%	-17.6%

Quarterly figures above are the most recent reported quarter for each company (Q1 FY28, quarter ended June 2026), compared with the year-ago and preceding quarter.

Download the Univest iOS App or Univest Android App to track Piramal Pharma, Sai Life Sciences and Neuland Laboratories live prices.

What Should Investors Look at Beyond These Numbers?

Beyond the metrics above, investors comparing these three crams and pharma cdmo names should track quarter-on-quarter revenue and margin trends, management commentary on demand and cost drivers, and any sector-specific regulatory developments, since a single-quarter snapshot can shift quickly.

Conclusion

Piramal Pharma vs Sai Life Sciences vs Neuland Laboratories highlights how differently three companies in the same crams and pharma cdmo segment can score across valuation, profitability and dividend metrics, even when operating in a similar space. This comparison does not declare a winner; investors should weigh these figures against their own research and risk appetite. Please read the disclaimer below before making any investment decision.

Disclaimer: Data and figures in this article are sourced from publicly available information as of September 2026 and may not reflect real-time prices. Please verify all data independently before making any investment decision. This comparison does not recommend or endorse any single stock over another; investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

FAQs on Piramal Pharma vs Sai Life Sciences vs Neuland Laboratories

What is the market cap difference between Piramal Pharma, Sai Life Sciences and Neuland Laboratories?

Ans. As of September 2026, Piramal Pharma has a market cap of approximately Rs 28,045 crore, Sai Life Sciences is at approximately Rs 34,201 crore, and Neuland Laboratories is at approximately Rs 28,859 crore.

Which of the three has the highest PE ratio?

Ans. Among Piramal Pharma, Sai Life Sciences and Neuland Laboratories, the PE ratios stand at NA, 94.54 and 57.98 respectively as of September 2026.

Which of the three has the highest ROE?

Ans. Piramal Pharma, Sai Life Sciences and Neuland Laboratories post ROE of -3.58%, 14.05% and 19.42% respectively as of September 2026.

Which of these three stocks pays the highest dividend yield?

Ans. Piramal Pharma, Sai Life Sciences and Neuland Laboratories carry dividend yields of 0.00%, 0.00% and 0.15% respectively.

What is the debt to equity ratio for Piramal Pharma, Sai Life Sciences and Neuland Laboratories?

Ans. Piramal Pharma carries a debt to equity of 0.70, Sai Life Sciences of 0.12, and Neuland Laboratories of 0.16.

Which of the three trades at the highest price to book value?

Ans. Piramal Pharma, Sai Life Sciences and Neuland Laboratories trade at price to book ratios of 3.43, 13.77 and 15.40 respectively.

Is one of Piramal Pharma, Sai Life Sciences or Neuland Laboratories better than the others?

Ans. This comparison does not declare one stock better than another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor's own criteria and research.